Takeda Pharmaceutical Coの空売り状況は、投資家がTakeda Pharmaceutical Coの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Takeda Pharmaceutical Co (NYSE:TAK) 株価情報, 空売り情報

Takeda Pharmaceutical Co

Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co Ltd

TransAKT Ltd

TAKIGAMI STEEL CONSTRCTN by Takigami Steel Construction Co. Ltd.

Takigami Steel Construction Co Ltd

TAKAMATSU CONSTRUCTION GR by TAKAMATSU CONSTRUCTION GROUP CO LTD

Takamatsu Construction Group Co Ltd

VOLATUS AEROSPACE INC by VOLATUS AEROSPACE INC.

Volatus Aerospace Inc

Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) reported quarterly sales of $185.78 million which missed the analyst consensus estimate of $210.45 million by 11.72 percent. This is a 1.36 percent decrease over sales of $188.34 million the same period last year.

Earnings

Earnings Misses

News

TLRY

Tilray Brands Q3 Sales $185.78M Miss $210.45M Estimate

Stock markets endured <a href="https://www.benzinga.com/hedge-funds/25/04/44676150/ceos-wall-street-titans-brace-for-sustained-market-downturn-theres-too-much-confidence-in-the-system">major swings this week</a>, with futures rising in after-hours trading on Monday after a volatile session. A brief rally was prompted by hopes of a delay in new tariffs, but those hopes were quickly dashed. Meanwhile, GameStop CEO Ryan Cohen, a vocal Trump supporter, is making headlines for his reaction to the <a href="https://www.benzinga.com/markets/25/04/44678625/did-trump-team-manipulate-tariff-formula-to-achieve-higher-rates-experts-weigh-in-as-they-think-whole-thing-was-rigged">latest developments.</a>
What Happened: Cohen, who has publicly expressed his support for Donald Trump through several posts on X, published a sarcastic comment in response to the latest round of U.S. tariffs: "I can't wait for my $10,000 made in the USA iPhone." 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I can't wait for my $10,000 made in the USA IPhone
&mdash; Ryan Cohen (@ryancohen) <a href="https://twitter.com/ryancohen/status/1908204902456656225?ref_src=twsrc%5Etfw">April 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
His remark came on the heels of <a href="https://www.benzinga.com/25/04/44677880/apple-reportedly-plans-to-move-more-iphone-production-to-india-amid-trump-tariff-fearscould-this-solve-the-300-price-hike-on-550-hardware">reports that electronics prices could increase</a> significantly due to the trade uncertainties, with Reuters approximating iPhone prices could climb by as much as 43%.
See Also: <a href="https://www.benzinga.com/markets/25/04/44656119/trump-tariffs-could-blow-up-apple-analyst-estimates-39-5-billion-impact">&#8216;Trump Tariffs Could Blow Up Apple&#8217;: Analyst Estimates $39.5 Billion Impact</a>
Why It Matters: The new tariffs are already impacting consumer goods and tech launches. Nintendo announced a postponement in pre-orders for its upcoming Switch 2, referencing the need to assess the "potential impacts of tariffs and evolving market conditions." For GameStop, a major retailer of consoles like the Switch, that delay could have <a href="https://www.benzinga.com/25/04/44672218/gamestop-enters-the-danger-zone-death-cross-flashes-but-ryan-cohen-isnt-flinching">noteworthy revenue implications</a>. Cohen's viral reaction highlights the tension between political support and business consequences.
As the market continues to react to changing trade policy, CEOs like Cohen are discovering themselves at the center of the conversation. His online remarks, while made seemingly in jest, reflect the wider concerns over how tariffs may impact consumer prices and shape corporate strategy moving forward.
Read Next: <a href="https://www.benzinga.com/news/25/04/44677532/howard-lutnick-says-army-of-millions-will-build-iphones-in-the-us-but-could-trumps-tariffs-make-the">Howard Lutnick Says Army Of Millions Will Build iPhones In The US, But Could Trump&#8217;s Tariffs Make The Premium Apple Flagship Cost $2,300?</a>
Image via Shutterstock

Equities

Markets

General

GameStop CEO Ryan Cohen's Support For Trump Faces New Test After He Posts '$10,000 iPhone' Tweet Amid Market Turmoil And Tariff Fallout

Guidance

Health Care

Given The Pending Transaction Pursuant To Which Walgreens Boots Alliance Will Be Acquired By Sycamore Partners, The Company Is Withdrawing Fiscal 2025 Guidance

WD-40 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.27 by 3.94 percent. The company reported quarterly sales of $146.10 million which missed the analyst consensus estimate of $154.41 million by 5.38 percent. This is a 5.03 percent increase over sales of $139.10 million the same period last year.

Earnings Beats

WDFC

WD-40 Q2 2025 Adj EPS $1.32 Beats $1.27 Estimate, Sales $146.10M Miss $154.41M Estimate

Jefferies analyst Peter Abramowitz initiates coverage on Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) with a Buy rating and announces Price Target of $80.

Price Target

Initiation

Analyst Ratings

Jefferies Initiates Coverage On Equity Lifestyle Props with Buy Rating, Announces Price Target of $80

Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares are trading higher premarket on Tuesday.
On Monday, the company disclosed a definitive deal to sell its Automotive Ethernet business to Infineon Technologies AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/IFNNY#OTC">IFNNY</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44674510/marvell-to-sell-automotive-ethernet-business-to-infineon-for-2-5-billion-in-cash" rel="noreferrer noopener">for $2.5 billion in an all-cash deal</a>.
The transaction includes Marvell's Brightlane Automotive Ethernet portfolio and related assets.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44674813/if-tariffs-shift-customer-spending-priorities-these-software-stocks-could-face-slow-growth" rel="noreferrer noopener">If Tariffs Shift Customer Spending Priorities, These Software Stocks Could Face Slow Growth</a>
The company projected this segment to generate $225 million to $250 million in revenue in 2025, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44678709/infineon-further-strengthens-its-number-one-position-in-automotive-microcontrollers-and-boosts-sys" rel="noreferrer noopener">with a gross margin of around 60%</a>.
Approved by Marvell's Board of Directors, the deal is expected to close by the end of 2025, pending regulatory approvals and standard closing conditions.
Matt Murphy, Chairman and CEO of Marvell said, "We believe this transaction delivers the strongest financial return for Marvell shareholders, given its compelling valuation."
Jochen Hanebeck, CEO of Infineon added, "We will leverage this highly complementary Ethernet technology by combining it with our existing, broad product portfolio to provide our customers with even more comprehensive, leading solutions for software-defined vehicles."
"The transaction will support our profitable growth strategy going forward, including new opportunities in the field of physical AI such as humanoid robots."
Last month, the company and TeraHop debuted PCIe Gen 6 over optics to boost AI data center speed and scalability at the Optical Networking and Communication <a target="_blank" href="https://www.benzinga.com/25/03/44517705/marvell-launches-next-gen-connectivity-to-meet-rising-ai-demands-in-data-infrastructure" rel="noreferrer noopener">Conference and Exposition (OFC)&nbsp;2025</a>.
Investors can gain exposure to MRVL via&nbsp;Spear Alpha ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRX#NASDAQ">SPRX</a>) and Innovator Deepwater Frontier Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOUP#NYSE">LOUP</a>).
Price Action: MRVL shares are up 3.82% at $52.95 premarket at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44653936/broadcom-and-marvell-poised-for-growth-as-nvidias-cpo-push-faces-delays-analyst-reveals" target="_blank" rel="noreferrer noopener">Rising Tide Of AI Is So Strong That Semiconductor Optical Industry Projects $30 Billion Total Addressable Market By 2029</a></li>
</ul>
Photo via Shutterstock

Large Cap

Asset Sales

Movers

IFNNY

LOUP

MRVL

SPRX

Marvell Offloads Auto Ethernet Segment To Infineon Tech For $2.5 Billion Cash

UNH REVERSES EARLY WEAKNESS ON SIGNAL &amp; CLIMBS OVER 20 POINTS
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/07210750/Screenshot-2025-04-07-at-5.01.56%E2%80%AFPM-940x1024.png" alt="" class="wp-image-9971" /></figure>
UnitedHealthcare Group, Inc. (UNH) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:04 AM on April 7th, a significant trading signal occurred for UnitedHealthcare Group, Inc. (UNH) as it demonstrated a Power Inflow at a price of $507.54. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in UNH&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in UNH&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for UNH, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like    <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>, which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE: The price at the time of the Power Inflow was $507.54. The returns on the High price ($529.17) and Close price ($524.70) after the Power Inflow are respectively 4.3% and 3.4%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Past Performance Not Indicative of Future Results

WIIM

Technicals

Signals

Trading Ideas

UnitedHealth Stock Up Over 4% After Key Signal, Amid Market Turmoil

Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.53 by 18.87 percent. This is a 47.5 percent decrease over earnings of $1.20 per share from the same period last year. The company reported quarterly sales of $38.59 billion which beat the analyst consensus estimate of $38.00 billion by 1.55 percent. This is a 4.15 percent increase over sales of $37.05 billion the same period last year.

Walgreens Boots Alliance Q2 2025 Adj EPS $0.63 Beats $0.53 Estimate, Sales $38.59B Beat $38.00B Estimate

AECOM Has Been Selected As A Design Development Partner For Australia's Largest Water Utility Sydney Water

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) with a Buy and maintains $3 price target.

Reiteration

MVST

HC Wainwright & Co. Reiterates Buy on Microvast Holdings, Maintains $3 Price Target

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and raises the price target from $81 to $92.

RYTM

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $92

Canaccord Genuity analyst William Plovanic maintains CVRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) with a Buy and lowers the price target from $23 to $18.

CVRX

Canaccord Genuity Maintains Buy on CVRx, Lowers Price Target to $18

As of March 31, 2025, AL's fleet was comprised of 487 owned aircraft and 57 managed aircraft, with 255 new aircraft on order from Airbus and Boeing set to deliver through 2029.
Aircraft Investments
<ul>
<li>Delivered 14 new aircraft from AL's orderbook including four Airbus A220s, eight Boeing 737-8s, one Boeing 737-9, and one Boeing 787-10.</li>
<li>Aircraft investments totaled approximately $800 million, with the majority occurring in the second half of the quarter.</li>
</ul>
Sales
<ul>
<li>Sold 16 aircraft to third-party buyers.</li>
<li>Aircraft sales proceeds for the quarter totaled approximately $520 million.</li>
</ul>
Russia Fleet Insurance Settlements
<ul>
<li>Received an aggregate of $328.5 million in cash insurance settlement proceeds in the first quarter of 2025.</li>
</ul>

Air Lease Updates Q1 2025 Activity: Delivers 14 New Aircraft, Sells 16, And Receives $328.5M In Insurance Settlements

Ryan Hanley will bring its extensive local knowledge, relationships, and technical expertise to Stantec, particularly around the Irish water sector. The firm delivers a broad range of services, creating solutions for local authorities, government departments, private clients, utility companies, and other influential organizations. The acquisition is an important part of Stantec's goal of expanding its presence in Ireland.

Stantec Acquires Ryan Hanley To Expand Presence In Ireland's Water Sector; Deal Terms Not Disclosed

RPM International Sees Q4 Sales To be Flat & Adjusted EBIT Of Low-Single-Digit Percentage Range

HC Wainwright &amp; Co. analyst Amit Dayal reiterates BioHarvest Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHST#NASDAQ">BHST</a>) with a Buy and maintains $14 price target.

BHST

HC Wainwright & Co. Reiterates Buy on BioHarvest Sciences, Maintains $14 Price Target

<a href="https://www.bloomberg.com/news/articles/2025-04-08/cvs-cfo-thomas-cowhey-said-to-plan-departure" title="https://www.bloomberg.com/news/articles/2025-04-08/cvs-cfo-thomas-cowhey-said-to-plan-departure">https://www.bloomberg.com/news/articles/2025-04-08/cvs-cfo-thomas-cowhey-said-to-plan-departure</a>

Insider Trades

Bloomberg Reported Monday, CVS Health Is Facing Activist Investor

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) with a Buy and lowers the price target from $25 to $22.

LXEO

Chardan Capital Maintains Buy on Lexeo Therapeutics, Lowers Price Target to $22

RPM International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) reported quarterly earnings of $0.35 per share which missed the analyst consensus estimate of $0.49 by 28.57 percent. This is a 32.69 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $1.48 billion which missed the analyst consensus estimate of $1.51 billion by 2.00 percent. This is a 3.05 percent decrease over sales of $1.52 billion the same period last year.

RPM International Q3 2025 Adj EPS $0.35 Misses $0.49 Estimate, Sales $1.48B Miss $1.51B Estimate

CVS Expects Financial Results To Meet Or Exceed FY25 Guidance

Press Releases

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

Takeda Recognized as a Top Employer in Canada for Third Consecutive Year

Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Comments

Takeda Pharmaceutical Co

空売り

Takeda Pharmaceutical Co (NYSE:TAK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル